Press Releases

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel) in an open-label, randomized.   Phase III study (CheckMate -057) evaluating previously-treated...

Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015. Jeffrey Simmons, senior vice president and president, Elanco Animal Health, will participate in a fireside chat at 2:20...

Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with...

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Monday, June 1, 2015, at 7 p.m. EDT (6 p.m. CDT) to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in...

Eli Lilly and Company (NYSE: LLY) announced today that pursuant to its previously announced cash tender offer for up to $1.6 billion aggregate principal amount (the "tender cap") of specified series of its outstanding debt.  ...

Eli Lilly and Company (NYSE: LLY) announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ...

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on June 11 to discuss data from the first two pivotal Phase III studies of baricitinib in rheumatoid arthritis.   Data...